Market closed
Adverum Biotechnologies/$ADVM
Adverum Biotechnologies shares are trading higher after the company reported its Q1 2025 financial results and provided updates on its pipeline, including the initiation of a significant gene therapy trial.
4 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adverum Biotechnologies
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Ticker
$ADVM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
155
ISIN
US00773U2078
Website
ADVM Metrics
BasicAdvanced
$43M
-
-$7.22
1.02
-
Price and volume
Market cap
$43M
Beta
1.02
52-week high
$10.14
52-week low
$1.78
Average daily volume
490K
Financial strength
Current ratio
3.565
Quick ratio
3.311
Long term debt to equity
325.293
Total debt to equity
352.653
Management effectiveness
Return on assets (TTM)
-48.76%
Return on equity (TTM)
-144.51%
Valuation
Price to revenue (TTM)
42.839
Price to book
1.62
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-0.381
Growth
Earnings per share change (TTM)
-29.80%
3-year earnings per share growth (CAGR)
-22.95%
What the Analysts think about ADVM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Adverum Biotechnologies stock.
ADVM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ADVM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ADVM News
AllArticlesVideos
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
GlobeNewsWire·2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Accesswire·6 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Adverum Biotechnologies stock?
Adverum Biotechnologies (ADVM) has a market cap of $43M as of May 16, 2025.
What is the P/E ratio for Adverum Biotechnologies stock?
The price to earnings (P/E) ratio for Adverum Biotechnologies (ADVM) stock is 0 as of May 16, 2025.
Does Adverum Biotechnologies stock pay dividends?
No, Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Adverum Biotechnologies dividend payment date?
Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders.
What is the beta indicator for Adverum Biotechnologies?
Adverum Biotechnologies (ADVM) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.